(Q36528747)

14 August 2017

1 reference

title

Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation (English)

1 reference

14 August 2017

1 reference

2

Caroline M Perry

1 reference

14 August 2017

Caroline Fenton

1

1 reference

14 August 2017

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

23

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

421-445

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-200623050-00006

14 August 2017

exact match

0 references

cites work

Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002512-200623050-00006

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002512-200623050-00006

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.

21 January 2018

1 reference

12 December 2020

Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management--TAP report No. 6.

1 reference

12 December 2020

Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy

1 reference

12 December 2020

Vascular targeting in photodynamic occlusion of subretinal vessels

1 reference

12 December 2020

Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration

1 reference

12 December 2020

Smoking and age-related macular degeneration: a review of association.

1 reference

12 December 2020

Photodynamic therapy for AMD: smaller is better!

1 reference

12 December 2020

Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7

1 reference

12 December 2020

Subfoveal hemorrhage after verteporfin photodynamic therapy in treatment of choroidal neovascularization

1 reference

12 December 2020

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy an

1 reference

12 December 2020

Verteporfin therapy in combination with triamcinolone: published studies investigating a potential synergistic effect.

1 reference

12 December 2020

Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia

1 reference

12 December 2020

Comparative study of the phototoxicity of two chrolin type photosensitizers, ATX-S10(Na) and verteporfin, on vascular endothelial and retinal pigment epithelial cells

1 reference

12 December 2020

Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration

1 reference

12 December 2020

Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration

1 reference

12 December 2020

Competitive quenching: a possible novel approach in protecting RPE cells from damage during PDT.

1 reference

12 December 2020

A functional profile of gene expression in ARPE-19 cells

1 reference

12 December 2020

Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization

1 reference

12 December 2020

Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

1 reference

12 December 2020

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

1 reference

12 December 2020

Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

1 reference

12 December 2020

Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case

1 reference

12 December 2020

Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.

1 reference

12 December 2020

A review of treatments for macular degeneration: a synopsis of currently approved treatments and ongoing clinical trials

1 reference

12 December 2020

CME review: A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization

1 reference

12 December 2020

Influence of treatment parameters on selectivity of verteporfin therapy

1 reference

12 December 2020

BDNF reduces the retinal toxicity of verteporfin photodynamic therapy

1 reference

12 December 2020

Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization

1 reference

12 December 2020

Risk factors for age-related macular degeneration: Pooled findings from three continents.

1 reference

12 December 2020

A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration

1 reference

12 December 2020

1 reference

12 December 2020

Photodynamic therapy in immune (non-oncological) disorders: focus on benzoporphyrin derivatives

1 reference

12 December 2020

Verteporfin in Photodynamic Therapy: report no. 5.

1 reference

12 December 2020

Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial

1 reference

12 December 2020

Photodynamic therapy for age-related macular degeneration: a candid appraisal

1 reference

12 December 2020

Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Repo

1 reference

12 December 2020

Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group

1 reference

12 December 2020

Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation--'beyond the TAP study'.

1 reference

12 December 2020

Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment

1 reference

12 December 2020

Joint effects of smoking history and APOE genotypes in age-related macular degeneration

1 reference

12 December 2020

Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy

1 reference

12 December 2020

Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy

1 reference

12 December 2020

The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data

1 reference

12 December 2020

Late-onset visual decline following successful treatment of subfoveal choroidal neovascularisation with photodynamic therapy

1 reference

12 December 2020

Clinical outcome and subjective quality of life after photodynamic therapy in patients with age-related macular degeneration

1 reference

12 December 2020

Photodynamic therapy in the treatment of subfoveal choroidal neovascularisation

1 reference

12 December 2020

The Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists--comments on the current therapy for neovascular AMD

1 reference

12 December 2020

Clinical pharmacokinetics of verteporfin

1 reference

12 December 2020

Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update

1 reference

12 December 2020

Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration

1 reference

12 December 2020

Current and future treatment options for nonexudative and exudative age-related macular degeneration.

1 reference

12 December 2020

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration

1 reference

12 December 2020

Age related macular degeneration

1 reference

12 December 2020

Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy

1 reference

12 December 2020

Review of first year result of photodynamic therapy on age-related macular degeneration in Chinese population

1 reference

12 December 2020

Improvement in quality of life from photodynamic therapy: a Canadian perspective

1 reference

12 December 2020

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therap

1 reference

12 December 2020

Effects of verteporfin therapy on central visual field function

1 reference

12 December 2020

Surgical management of age-related macular degeneration

1 reference

12 December 2020

Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor

1 reference

12 December 2020

Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.

1 reference

12 December 2020

Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.

1 reference

12 December 2020

Effects of verteporfin therapy on contrast on sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4.

1 reference

12 December 2020

Improvement after verteporfin therapy

1 reference

12 December 2020

Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.

1 reference

12 December 2020

Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up.

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of laser beam intensity profiles produced by photodynamic therapy (PDT) and transpupillary thermotherapy (TTT) lasers.

1 reference

12 December 2020

Photodynamic therapy with verteporfin: observations on the introduction of a new treatment into clinical practice

1 reference

12 December 2020

Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.

1 reference

12 December 2020

Self-reported visual functioning and quality of life in age-related macular degeneration.

1 reference

12 December 2020

Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients

1 reference

12 December 2020

Prevalence and risk factors for refractive errors in adult Chinese in Singapore

1 reference

12 December 2020

Photodynamic therapy of subfoveal recurrences after laser photocoagulation of extrafoveal choroidal neovascularization in pathologic myopia

1 reference

12 December 2020

The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration

1 reference

12 December 2020

Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19

1 reference

12 December 2020

Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation

1 reference

12 December 2020

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

1 reference

12 December 2020

Variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration

1 reference

12 December 2020

Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3.

1 reference

12 December 2020

Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV.

1 reference

12 December 2020

Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7.

1 reference

12 December 2020

10.2165/00002512-200623050-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

14 August 2017

1022993688

0 references

1 reference